Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Nxl 104
2. Nxl-104
3. Nxl104
1. 1192500-31-4
2. Avibactam Free Acid
3. Nxl104
4. Ave-1330a Free Acid
5. Avibactam (free Acid)
6. Nxl-104 Free Acid
7. Chembl1689063
8. Chebi:85984
9. 06mfo7817i
10. [(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] Hydrogen Sulfate
11. 396731-14-9
12. (2s,5r)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
13. 1,6-diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1r,2s,5r)-rel-
14. (1r,2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl Hydrogen Sulfate
15. Avibactam [inn]
16. Avibactam [usan:inn]
17. Unii-06mfo7817i
18. Avibactamfreeacid
19. Sulfuric Acid, Mono((1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) Ester
20. Sulfuric Acid, Mono[(1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl] Ester
21. Unii-7352665165
22. Avibactam [mi]
23. Avibactam [usan]
24. Avibactam [who-dd]
25. Schembl1666807
26. Avibactam, (+/-)-
27. Gtpl10761
28. Dtxsid901026066
29. Amy24028
30. Avi
31. Zavicefta Component Avibactam
32. Zinc9302239
33. Bdbm50339145
34. Avibactam Component Of Zavicefta
35. Cs-0593
36. Db09060
37. Ac-35749
38. Hy-14879
39. E80372
40. Q15410251
41. Trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octan-2-carboxamide
42. (1r,2s,5r)-7-oxo-6-sulfooxy-1,6-diazabicyclo(3.2.1)octane-2-carboxamide
43. 794508-22-8
Molecular Weight | 265.25 g/mol |
---|---|
Molecular Formula | C7H11N3O6S |
XLogP3 | -1.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 265.03685625 g/mol |
Monoisotopic Mass | 265.03685625 g/mol |
Topological Polar Surface Area | 139 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 457 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
AVYCAZ (ceftazidime-avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older. AVYCAZ is also indicated for the treatment of complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older.
FDA Label
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
Route of Elimination
Avibactam and ceftazidime are excreted mainly by the kidneys.
Volume of Distribution
The steady state volumes of distribution of avibactam and ceftazidime is 22.2L and 17L respectively.
Clearance
Avibactam and ceftazidime has a clearance of ~12L/h and ~7L/h respectively.
No metabolism of avibactam was observed in human liver preparations. Unchanged avibactam is the major drug-related component in human plasma and urine. 80-90% of ceftazidime is eliminated as unchanged .
Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.
Avibactam is a non- lactam -lactamase inhibitor that inactivates some -lactamases (Ambler class A -lactamases, including Klebsiella pneumoniae carbapenemases, Ambler class C and some Ambler class D -lactamases) by a unique covalent and reversible mechanism, and protects ceftazidime from degradation by certain -lactamases. Avibactam rapidly reaches the periplasm of bacteria at high enough concentrations to restore activity of ceftazidime against ceftazidime-resistant, -lactamase-producing strains. Avibactam does not decrease the activity of ceftazidime against ceftazidime susceptible organisms.
About the Company : Jing Jing Pharmaceutical Co., Ltd., founded in October 2007, covers an area of 200 mu, registered capital of 257.28 million yuan, and employees of more than 700 people, is a high-t...
About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Reply
10 Dec 2024
Reply
17 Jul 2023
Reply
25 Jan 2023
Reply
30 Aug 2022
Reply
25 Apr 2022
Reply
29 Jan 2022
Reply
11 Aug 2021
Reply
10 Aug 2021
Reply
01 Jun 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?